Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) issued its earnings results on Wednesday. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.36) by $0.22, Zacks reports. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%.

Keros Therapeutics Trading Up 0.3 %

KROS traded up $0.03 during trading hours on Wednesday, hitting $10.94. The company’s stock had a trading volume of 1,282,584 shares, compared to its average volume of 1,621,534. The business’s 50-day moving average price is $12.88 and its 200-day moving average price is $40.20. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The stock has a market cap of $443.15 million, a price-to-earnings ratio of -2.10 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Scotiabank cut their target price on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research report on Thursday, January 16th. Oppenheimer dropped their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research note on Thursday, January 16th. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Truist Financial cut their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Finally, Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.